Viloxazine Shortage: What Providers and Prescribers Need to Know in 2026

Viloxazine Shortage: What Providers and Prescribers Need to Know in 2026

If your patients are reporting difficulty filling Viloxazine (Qelbree) prescriptions, you're not alone. While Viloxazine is not on the FDA's drug shortage list, localized availability challenges have persisted into 2026 — driven by brand-only status, cost-related pharmacy stocking decisions, and increased demand for non-stimulant ADHD treatments. This briefing covers what you need to know to manage these challenges in your prescribing practice.

Complete Timeline: How We Got Here

April 2021: FDA approves Viloxazine extended-release capsules (Qelbree) for ADHD in children and adolescents aged 6–17. Supernus Pharmaceuticals launches the product as the first new non-stimulant ADHD medication in over a decade.

March 2022: FDA expands approval to include adults aged 18 and older, significantly broadening the eligible patient population.

2022–2023: Prescribing volumes grow steadily as clinicians adopt Viloxazine as an alternative to stimulants and Atomoxetine. Coincides with the national Adderall shortage, accelerating interest in non-stimulant options.

2024–2025: Ongoing stimulant shortages continue to drive demand for Viloxazine. Patients report increasing difficulty finding Qelbree at chain pharmacies. Supernus maintains manufacturing, but distribution remains uneven due to pharmacy stocking economics.

2026 (current): Viloxazine remains off the FDA shortage list. Availability challenges persist as a localized distribution issue rather than a manufacturing shortfall. No generic alternatives have entered the market.

Current Availability Landscape for Prescribers

Supply Chain Status

Supernus Pharmaceuticals continues to manufacture and distribute Viloxazine without reported production constraints. The availability issues your patients experience are primarily at the pharmacy level — not the manufacturing level. The medication exists in the wholesale supply chain, but individual pharmacies may not stock it due to cost or ordering constraints.

Prior Authorization Complexity

Viloxazine coverage varies significantly across payers:

• Most commercial plans: Require prior authorization and may mandate step therapy (trial of a stimulant and/or Atomoxetine first)
• Medicaid: Coverage varies by state; some states have added Viloxazine to their preferred drug lists while others require PA
• Medicare Part D: Generally covered with prior authorization; Tier 3 or higher placement is typical

The PA process for Viloxazine typically requires documentation of: ADHD diagnosis, previous treatment trials and their outcomes, and clinical rationale for a non-stimulant option (e.g., substance use history, stimulant intolerance, patient preference, comorbid anxiety).

Indication-Specific Coverage

Insurance coverage is strongest for the FDA-approved indication of ADHD. Off-label use for depression or anxiety — despite Viloxazine's historical use as an antidepressant in Europe — is generally not covered and may trigger claim denials.

The Real-World Availability Picture

Supply Chain Mechanics

The distribution path for Viloxazine follows the standard model: Supernus Pharmaceuticals → national wholesalers (McKesson, Cardinal Health, AmerisourceBergen) → individual pharmacies. At each step, allocation decisions can limit what reaches the pharmacy shelf.

Wholesalers allocate inventory based on a pharmacy's historical purchasing patterns. A pharmacy that hasn't regularly stocked Viloxazine will have a lower allocation — creating a chicken-and-egg problem where low stocking leads to low allocation, which perpetuates low stocking.

Dose-Specific Variation

Some doses may be more readily available than others. The 200 mg capsule — the most commonly prescribed adult starting dose — tends to have the most consistent availability. The 100 mg and 150 mg capsules, which serve pediatric patients and dose titration, may be less consistently stocked.

Regional Disparities

Urban areas with multiple pharmacy options generally offer better access. Rural areas and regions with fewer independent pharmacies may face more significant challenges. Patients willing to expand their search radius often find better results.

Cost and Access: The Numbers Your Patients Are Seeing

List Price

Qelbree's retail price ranges from $350–$500 per month, depending on dose and pharmacy. This is a significant barrier for patients without adequate insurance coverage.

Manufacturer Savings Programs

Supernus offers a Qelbree Savings Card for commercially insured patients, potentially reducing copays to $0 (subject to maximum benefit limits). This program does not apply to patients with government insurance (Medicare, Medicaid, Tricare).

Medicare/Medicaid Coverage

Medicare Part D plans generally cover Viloxazine with prior authorization. Medicaid coverage varies by state. For patients on government insurance who face high out-of-pocket costs, the Supernus Cares Patient Assistance Program may provide free medication to qualifying individuals.

Patient Assistance Programs

For uninsured or underinsured patients:

• Supernus Cares PAP: Provides Qelbree at no cost for income-eligible patients
• NeedyMeds: needymeds.org — comprehensive database of assistance programs
• RxAssist: rxassist.org — patient assistance program directory

Tools and Resources for Your Practice

• Medfinder Provider Portal: Search for pharmacies with Viloxazine in stock on behalf of your patients. The dedicated support team can help locate the medication and connect patients with pharmacies that have it available.
• FDA Drug Shortage Database: accessdata.fda.gov/scripts/drugshortages — monitor official shortage declarations
• Qelbree HCP Resources: Clinical information, savings card enrollment, and PAP applications available through the Qelbree website for healthcare professionals

Looking Ahead

Several developments may impact Viloxazine access in the coming years:

• Generic entry: Patent protection for Qelbree extends for several more years. No generic competition is expected in the near term, meaning the brand-only cost and distribution challenges will persist.
• Payer policy evolution: As Viloxazine builds a longer track record, some payers may loosen step therapy requirements. Monitor formulary updates from major plans in your area.
• Prescribing trend impacts: If stimulant shortages continue to resolve, some of the demand pressure on Viloxazine may ease, potentially improving pharmacy-level availability.
• Telehealth prescribing: Viloxazine's non-controlled status makes it well-suited for telehealth prescribing, which may help expand patient access to prescribers even in underserved areas.

Final Thoughts

Viloxazine occupies an important niche in the ADHD treatment landscape as a non-stimulant, non-controlled option with a novel mechanism of action. The availability challenges your patients face are real but manageable with the right strategies.

As a prescriber, you can make a meaningful difference by:

1. Using the Medfinder provider portal to help patients locate Viloxazine in stock
2. Proactively helping with prior authorization documentation
3. Connecting patients with the Qelbree savings card and patient assistance programs
4. Having contingency plans (alternative medications) ready for patients who can't access Viloxazine

Share this patient-facing update with patients who are struggling with availability. For a step-by-step practice guide, see our article on how to help your patients find Viloxazine in stock.